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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the efficacy and tolerability of oxcarbazepine when used as an add-on treatment for patients with drug-resistant partial epilepsy.
B A C K G R O U N D
Description of the condition
Epilepsy is a disease arising from an enduring and pathological ex-
cessive discharge of a set of neurons in the brain, clinically charac-
terised by recurrent unprovoked epileptic seizures or in the context
of an epilepsy syndrome. There are many causes, alongside sev-
eral clinical and electroencephalographic manifestations that can
result in epilepsy (Fisher 2014). The condition is associated with
considerable physical, cognitive, psychiatric and psychological co-
morbidity (LaFrance 2008; Burton 2012).
Epilepsy is common worldwide; a meta-analysis of 65 studies es-
timated lifetime prevalence in high-income countries as 5.8 per
1000 whereas in resource-poor countries the estimate was 10.3
per 1000 and 15.4 per 1000 in urban and rural areas, respectively
(Bell 2014).
The United Kingdom General Practice Study of Epilepsy found
60% of epilepsies to be convulsive, of which around two-thirds
comprise partial seizures or partial with secondary generalisation
(Sander 1990; Shorvon 2014).
Epilepsy is commonly treated with antiepileptic drugs (AEDs)
with many patients rendered seizure free. Unfortunately, an esti-
mated 30%of epilepsy cases are resistant to conventional AED reg-
imens and can require several agents to control seizures (Cockerell
1995; Kwan 2000), especially partial seizures which originate from
one area of the brain (Panebianco 2015). Drug resistant epilepsy is
defined as “failure of adequate trials of two tolerated and appropri-
ately chosen and used AED schedules (whether as monotherapies
or in combination) to achieve sustained seizure freedom” (ILAE
2009). There are also non-medical interventions for epilepsy avail-
able such as vagal nerve stimulation or surgery (Panebianco 2015;
West 2015).
The present review will focus upon the effects of oxcarbazepine on
seizures, side effects, cognition and quality of life when used as an
add-on treatment for patients with drug-resistant partial epilepsy.
Description of the intervention
Oxcarbazepine is an analogue of carbamazepine. Oxcarbazepine
is thought to have certain advantages over carbamazepine. In par-
ticular, there are fewer side effects and the dose can be titrated to
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a therapeutic dose more quickly (Grant 1992). Oxcarbazepine is
an AED used as monotherapy for children and adults with partial
onset seizures. It is associated with level A and level D evidence
for efficacy and effectiveness for children and adults, respectively
(Glauser 2013).
How the intervention might work
AEDs have numerous modes of action. They aim to target neu-
ronal receptors in order to either reduce neuronal excitation or
increase inhibition, thus deceasing the likelihood of seizure dis-
charges (NICE 2012). Oxcarbazepine has been shown to exert
antiepileptic activity by blockade of voltage-dependent sodium
channels in the brain. Based on in vitro and in vivo findings
and compared with antiepileptic drugs such as carbamazepine,
phenytoin and phenobarbital, oxcarbazepine has a low propen-
sity for drug-drug interactions (Flesch 2004). However the drug
is metabolised hepatically, being rapidly reduced by cytosolic en-
zymes in the liver to its monohydroxy derivative (MHD), which is
responsible for the pharmacological effect of the drug. Therefore
oxcarbazepine could potentiate other AEDs that are metabolised
hepatically. At oxcarbazepine doses above 1.2g, a 40% increase
in the concentration of phenytoin and a 15% increase in pheno-
barbital levels were observed. Furthermore,oxcarbazepine is asso-
ciated with decreased clearance with moderate to severe renal im-
pairment. Therefore dose adjustments are necessary in situations
of AED polypharmacy or moderate to severe renal impairment
(Flesch 2004).
Why it is important to do this review
A large amount of evidence has been accrued regarding the efficacy
and tolerability of new AEDs. The International League against
Epilepsy and other organisations have produced guidelines on how
to select new AEDs (Kang 2012). NewAEDs have been tested and
used with success, mainly as add-on therapies to standard drugs
such as phenytoin, carbamazepine and valproate. The majority
of trials investigating add-on therapy with AEDs have recruited
patients with partial epilepsy (experiencing simple partial and/or
complex partial and/or secondary generalised tonic-clonic seizures;
Commission 1989) that have been resistant to antiepileptic drug
treatment.
The introduction of several new AEDs means that systematic re-
views are needed to determine their effect as add-on agents for
people with partial seizures. These reviews will help inform clini-
cians on the best add-on agents to use for their patients (Marson
1997; Privitera 1999). Therefore we present a systematic review of
oxcarbazepine as an add-on treatment in drug-resistant epilepsy.
O B J E C T I V E S
To assess the efficacy and tolerability of oxcarbazepine when used
as an add-on treatment for patients with drug-resistant partial
epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
To be included in the review studies need to meet the following
criteria:
1. randomised controlled trials (RCTs), including quasi-
randomised trials in which the method of allocation
concealment is inadequate;
2. double, single or unblinded trials;
3. placebo-controlled or active-controlled studies;
4. parallel group or cross-over studies. For cross-over studies,
we plan to use the first treatment period as a parallel trial.
Types of participants
Adults and children with drug-resistant partial epilepsy, as defined
by The International League Against Epilepsy (ILAE 2009). Par-
ticipants who have undergone other interventions to treat epilepsy,
such as surgery, vagal nerve stimulation or ketogenic diet, will be
included.
Types of interventions
1. The active treatment group received therapy with
oxcarbazepine in addition to their usual treatment.
2. The control group received a placebo, an alternative
antiepileptic drug or a different dose of oxcarbazepine in
addition to their usual treatment.
Types of outcome measures
Primary outcomes
(1) Median percentage seizure reduction per 28 days
The median percentage seizure reduction every 4 weeks in the
treatment period compared to the pre-randomisation baseline pe-
riod. This outcome is commonly reported in this type of study,
and can be calculated for studies that do not report it, provided
that baseline seizure data were recorded.
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(2) Fifty per cent or greater reduction in seizure frequency
The proportion of patients with a 50% or greater reduction in
seizure frequency in the treatment period compared to the pre-ran-
domisation baseline period. This outcome is commonly reported
in this type of study, and can be calculated for studies that do not
report it, provided that baseline seizure data were recorded.
(3) Adverse effects
The proportion of patients experiencing any of the following side
effects:
1. Ataxia
2. Dizziness
3. Fatigue
4. Nausea
5. Somnolence
6. Headache
7. Hyponatraemia
8. Vertigo
9. Diplopia
10. Rash
11. Tremor
12. Pyrexia
13. Abnormal gait
14. Abdominal pain
15. Nystagmus
16. Viral infection
17. Vomiting
18. Abnormal vision
19. Any other adverse event
Secondary outcomes
(1) Seizure freedom
The proportion of patients with an 100% reduction in seizure fre-
quency in the treatment period compared to the pre-randomisa-
tion baseline period. This outcome is commonly reported in this
type of study and can also be calculated in studies that do not
report it, provided that baseline seizure data were recorded.
(2) Treatment withdrawal
The proportion of patients withdrawing from the treatment dur-
ing the course of the treatment period was chosen as a measure of
’global measure of tolerability’. In studies of relatively short dura-
tion, treatment is unlikely to be withdrawn due to lack of efficacy
and any treatment withdrawal is likely due to side effects.
(3) Cognitive effects
At present, there is no consensus as to which instruments should
be used to assess the effects of AEDs on cognition. As a result
the assessment of cognitive effects is likely to be approached in a
heterogeneous way (Cochrane 1998).
(4) Quality of life
Once again, there is no consensus as to which instruments should
be used to assess this and we expect to see significant heterogeneity
in the outcome measures used.
Search methods for identification of studies
Electronic searches
We will search the following databases. There will be no language
restrictions.
• Cochrane Epilepsy Group Specialized Register using the
search strategy set out in Appendix 1.
• Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO) using the search strategy set out in Appendix 2.
• MEDLINE (Ovid) 1946 to present using the search
strategy set out in Appendix 3.
• ClinicalTrials.gov using the search terms: oxcarbazepine
AND epilepsy.
• WHO International Clinical Trials Registry Platform
(ICTRP) using the search terms: oxcarbazepine AND epilepsy
NOT NCT*.
Previously SCOPUS was searched as an alternative to EMBASE,
but this is no longer necessary, because randomised and quasi-
randomised controlled trials in EMBASE are now included in
CENTRAL.
Searching other resources
References from published studies
We will review the reference lists of retrieved studies to search for
additional reports of relevant studies.
Efforts to identify unpublished studies
Unpublished data will be sought fromNovartis (the manufacturer
of oxcarbazepine). The results of the identifiedunpublished studies
will be compared with results from published studies to assess the
presence of publication bias.
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Other
We will ask colleagues if they are aware of any studies that we may
have missed.
Data collection and analysis
Selection of studies
Two review authors (CJ and MA) will independently assess the
titles and abstracts identified from the searches and exclude any
irrelevant studies. The same two authors will then review the full-
text papers for inclusion. Any disagreements will be resolved by
mutual discussion and if necessary the opinion of a third author
(AGM).
Data extraction and management
The same review authors will extract the following information
from included trials (again, any disagreements will be resolved by
mutual discussion).
Methodological trial design
(a) Method of concealing randomisation.
(b) Method of blinding.
(c) Whether any patients had been excluded from reported anal-
yses.
(d) Duration of baseline period.
(e) Duration of treatment period.
(f )Dose(s) of oxcarbazepine tested and potential comparator AED
treatment type and dose.
Patient/demographic information
(a) Number of patients allocated to each treatment group.
(b) Age/sex.
(c) Seizure types.
(d) Seizure frequency during baseline period.
(e) Number of background drugs.
Where necessary, original authors will be asked to confirm the
following:
(a) the method of randomisation;
(b) the total number of patients randomised to each group;
(c) the number of patients in each group achieving a 50%or greater
reduction in seizure frequency per treatment group;
(d) the number of patients having treatment withdrawn post ran-
domisation per treatment group.
For those excluded:
(a) the reason for exclusion;
(b) whether any of those excluded completed the treatment phase;
(c) whether any of those excluded had a 50% or greater reduction
in seizure frequency during the treatment phase.
Outcomes
The number of patients experiencing each outcome (see Types of
outcome measures) will be recorded per randomised group.
Assessment of risk of bias in included studies
Two review authors (MA, CJ) will independently assess the risk of
bias for each trial in accordance with the Cochrane ’Risk of bias’
tool as described in theCochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). Any disagreements will be discussed
and if necessary the opinion of a third review author (AGM) will
be sought. Studies will be rated as having a high, low or unclear
risk of bias for six domains applicable to RCTs: randomisation
sequence, allocation concealment, blinding, incomplete data out-
come, selective outcome reporting and other sources of bias. We
will also assess the potential impact of outcome reporting bias by
including an Outcome Reporting Bias in Trials (ORBIT) table in
the review (Kirkham 2010).
Measures of treatment effect
For dichotomous outcomes such as seizure reduction, seizure free-
dom, adverse effects and treatment withdrawal we plan to report
risk ratios (RRs) using 95% confidence intervals.
If it is possible to combine continuous outcomes, such as cognitive
effects and quality of life, in a meta-analysis, ideally we plan to
report the mean difference. However as we expect to see signifi-
cant variability, we plan to report the standardised mean difference
(SMD). In the event that there is significant heterogeneity of out-
come measures and meta-analysis is deemed to be inappropriate,
we plan to report the results of these outcomes narratively.
Unit of analysis issues
In the event that cross-over trials are included in this review, we
plan to include results from the first arm of the trial in meta-
analyses. However, if these data are not available and the cross-
over trial has used adequate methodology (for example, sufficient
wash-out periods), we plan to carry out a generic inverse variance
meta-analysis to combine data.
If trials have more than one treatment arm (for example, differ-
ent doses of oxcarbazepine versus a control group), the treatment
groups will be combined for meta-analysis and the dosage effects
will be reported narratively.
In trials with more than one treatment arm, using two different
AEDs, we will complete two comparisons; one comparing oxcar-
bazepine with the placebo and one comparing oxcarbazepine with
the other treatment.
Dealing with missing data
In the event of missing data, reasons for this will be sought by
contacting study authors in order to conclude whether data are
missing at random or not.
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Assessment of heterogeneity
Clinical andmethodological heterogeneity will be assessed visually
by two authors (MA, CJ) independently. We expect to see some
differences in control groups, outcome measures and time scales.
We do not expect significant clinical or methodological hetero-
geneity to the degree to which meta-analysis would be inappro-
priate.
The same two authors plan to assess visually the clinical and
methodological heterogeneity of the included studies, and plan to
use an I2 statistic and a Chi2 test where applicable to assess statis-
tical heterogeneity. We judge a Chi2 P value of less than 0.1 and
I2greater than 50% to indicate statistical heterogeneity.
Assessment of reporting biases
We plan to request protocols from study authors and investigate
outcome reporting bias using theORBITmatrix system (Kirkham
2010).
To examine publication bias, we will search for unpublished data
by carrying out a comprehensive search of multiple sources and
requesting any unpublished data from study authors. We also plan
to look for small study effects to establish the likelihood of publi-
cation bias.
Data synthesis
Ideally we plan to combine data in a fixed-effects meta-analysis.
However, where there is significant clinical, methodological or
statistical heterogeneity, wewill combineddata in a random-effects
meta-analysis.
Subgroup analysis and investigation of heterogeneity
Where possible, we will stratify subgroup analysis by: type of con-
trol group, clinical sample (adults or children), duration of treat-
ment, treatment dose and number of concomitant AEDs.
Sensitivity analysis
In the event of any peculiarities or inconsistencies being identified,
we will carry out a sensitivity analysis. To do this, we will include
only studies rated as having low risk of bias in a second meta-
analysis and results from this will be compared to the overall meta-
analysis.
Summarising and interpreting results
We will use the GRADE approach to interpret findings (
Schunemann 2011). We will use GRADE Profiler Software
(GRADEPro 2004), and import data from Review Manager 5
(RevMan 2014), to create ’Summary of findings’ tables for each
comparison included in the review for the primary outcomes.
The ’Summary of findings’ table for each comparison will include
information on overall quality of the evidence from the trials and
information of importance for healthcare decision making. The
GRADE approach determines the quality of evidence on the ba-
sis of an evaluation of eight criteria (risk of bias, inconsistency,
indirectness, imprecision, publication bias, effect size, presence of
plausible confounding that will change effect and dose-response
gradient). We will use these to guide our conclusions and recom-
mendations.
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A P P E N D I C E S
Appendix 1. Epilepsy Specialized Register search strategy
#1 actinium or barzepin or carbox or deprectal or “gp 47680” or lonazet or ocbz or oxalepsy or oxcarbamazepine or oxcarbazepine or
oxetol or oxpin or oxrate or “oxtellar xr” or oxypine or pharozepine or prolepsi or timox or trexapin or trileptal or trileptin
#2 INREGISTER
#3 #1 AND #2
#4 (monotherap* NOT (adjunct* OR “add-on” OR “add on” OR adjuvant* OR combination* OR polytherap*)):TI
#5 #3 NOT #4
Appendix 2. CENTRAL via CRSO search strategy
#1 actinium OR barzepin OR carbox OR deprectal OR “gp 47680” OR lonazet OR ocbz OR oxalepsy OR oxcarbamazepine OR
oxcarbazepine OR oxetol OR oxpin OR oxrate OR “oxtellar xr” OR oxypine OR pharozepine OR prolepsi OR timox OR trexapin
OR trileptal OR trileptin
#2 (epilep* OR seizure* OR convuls*):TI,AB,KY
#3 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES
#4 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#5 (#2 OR #3 OR #4) NOT INMEDLINE
#6 #1 AND #5
#7 (monotherap* not (adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*)):TI
#8 #6 NOT #7
Appendix 3. MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011).
1. (actinium or barzepin or carbox or deprectal or “gp 47680” or lonazet or ocbz or oxalepsy or oxcarbamazepine or oxcarbazepine or
oxetol or oxpin or oxrate or “oxtellar xr” or oxypine or pharozepine or prolepsi or timox or trexapin or trileptal or trileptin).tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. (monotherap$ not (adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$)).ti.
16. 14 not 15
17. remove duplicates from 16
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